The stock's fall snapped a two-day winning streak.

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

Highlights,Bristol-Myers Squibb beats quarterly earnings estimates.,Dividend increased, maintaining strong returns.,Insider ...

Bristol Myers Squibb is doubling down on a partnership with Medidata, signing a multiyear agreement to continue using the ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

Hyderabad: The queue of global pharma giants wanting to make Hyderabad their new home for drug discovery and tech centres is ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.